Proceeds to fund clinical development of DIAG723, a first-in-class, disease-modifying therapy designed to correct the root cause of hereditary hemorrhagic telangiectasia and pulmonary arterial ...
By using a patient's DNA to craft personalized drug treatments, doctors can increase the efficacy and better the outcomes of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback